Abstract
Marleen Taute, Paulina Tegethoff, Anna Hufnagel, Sophia Leonhardt, Selim Üstün Gürsel, Alexander Jethwa, Tobias Bittner, Daniel Keeser, Jan Haeckert, Julia Utecht, Boris Papazov, Boris-Stephan Rauchmann
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Challenges in the practical implementation of blood biomarkers for Alzheimer's disease
10.1016/j.lanhl.2024.07.013 · 2024
Association between modifiable risk factors and levels of blood-based biomarkers of Alzheimer’s and related dementias in the look AHEAD cohort
2024
The impact of exercise on blood-based biomarkers of Alzheimer’s disease in cognitively unimpaired older adults
10.1007/s11357-024-01130-2 · 2024
Physical activity and blood-based biomarkers of neurodegeneration in community dwelling Australians from ISLAND (Island study linking ageing and neurodegenerative disease)
2025
Associations between moderate-to-vigorous physical activity, p-tau181, and cognition in healthy older adults with memory complaints: a secondary analysis from the MAPT
10.1016/j.lanhl.2024.100678 · 2025
Modifiable risk factors for dementia, cognition, and plasma phosphorylated tau 181 in a large-scale cohort of Australian older adults
10.1016/j.neurobiolaging.2023.06.018 · 2023
Physical activity, Alzheimer plasma biomarkers, and cognition
10.1001/jamanetworkopen.2025.0096 · 2025
Associations between sleep quality, plasma neurofilament light, and cognition in older adults without dementia
10.1038/s41398-025-03389-1 · 2025
Blood-based biomarkers of Alzheimer's disease and incident dementia in the community
10.1038/s41591-025-03605-x · 2025
ISLAND campus: a fee-free formal university educational intervention in mid- to later-life to reduce modifiable risk factors for dementia and improve cognition
10.3389/fnagi.2024.1479926 · 2024
Lifestyle factors and plasma biomarkers of Alzheimer’s disease: a narrative review
10.1016/j.tjpad.2025.100130 · 2025
Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 birth cohort study in Gothenburg
10.1212/wnl.0000000000207419 · 2023
Confounding factors of Alzheimer's disease plasma biomarkers and their impact on clinical performance
10.1002/alz.12787 · 2023
Body mass index and blood volume influence plasma biomarkers and positron emission tomography classification in preclinical Alzheimer's disease
10.1002/alz.70765 · 2025
Blood biomarkers of Alzheimer’s disease in Australians habitually consuming various plant-based diets
10.1177/13872877251351549 · 2025
Levels of Alzheimer’s disease blood biomarkers are altered after food intake-a pilot intervention study in healthy adults
10.1002/alz.13163 · 2023
Diversity in Alzheimer’s disease drug trials: the importance of eligibility criteria
10.1002/alz.12433 · 2022
Has dementia research lost its sense of reality? A descriptive analysis of eligibility criteria of Dutch dementia research protocols
2016
US adults’ likelihood to Participate in dementia prevention drug trials: results from the National Poll on healthy aging
10.14283/jpad.2022.86 · 2023
Exploring the effect of eligibility criteria on AD severity and severe adverse event in eligible patients
2023
2022 Alzheimer's disease facts and figures
10.1002/alz.12638 · 2022
Understanding the impact of sex and gender in Alzheimer’s disease: a call to action
10.1016/j.jalz.2018.04.008 · 2018
The role of sex and gender in the selection of Alzheimer patients for clinical trial pre-screening
10.1186/s13195-021-00833-4 · 2021
Representativeness of samples enrolled in Alzheimer's disease research centers
2023
Together we make the difference: National Strategy for recruitment and participation in Alzheimer’s and related dementias clinical research
10.18865/ed.30.s2.705 · 2020
Unresolved referenced work
Kept as external metadata until matched
Systematic review: representativeness of participants in RCTs of acetylcholinesterase inhibitors
10.1371/journal.pone.0124500 · 2015
Associations of midlife lifestyle and health factors with long-term changes in blood-based biomarkers of Alzheimer’s disease and neurodegeneration
10.3233/jad-221287 · 2023
Application of the revised criteria for diagnosis and staging of Alzheimer’s disease: drug development and clinical practice
2024
The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
10.1016/j.jalz.2011.03.005 · 2011
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease
10.1016/j.jalz.2011.03.008 · 2011
Plasma biomarkers of amyloid, tau & neuroinflammation in Alzheimer's disease and corticobasal syndrome
10.1007/s00406-025-02013-z · 2025
Unresolved referenced work
2025
The consortium to establish a registry for Alzheimer’s disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer’s disease
10.1212/wnl.39.9.1159 · 1989
“Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician
10.1016/0022-3956(75)90026-6 · 1975
The clinical dementia rating (CDR): current version and scoring rules
10.1212/wnl.43.11.2412-a · 1993
Genuine memory deficits in dementia
10.1080/87565648709540361 · 1987
Microglial activation and connectivity in Alzheimer disease and aging
10.1002/ana.26465 · 2022
Biobanking in everyday clinical practice in psychiatry-the Munich mental health biobank
2022
Measuring sleep quality in older adults: a comparison using subjective and objective methods
10.3389/fnagi.2015.00166 · 2015
The potential clinical value of plasma biomarkers in Alzheimer's disease
10.1002/alz.13455 · doi-reference
Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies
10.1038/s41582-019-0228-7 · doi-reference
Linking lipids to Alzheimer’s disease: cholesterol and beyond
10.1038/nrn3012 · doi-reference
CSF and blood glial fibrillary acidic protein for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis
10.1016/j.arr.2024.102485 · doi-reference
Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease
10.1038/s41591-018-0304-3 · doi-reference
Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia
10.1038/s41591-020-0755-1 · doi-reference
Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status
10.1001/jamaneurol.2019.1632 · doi-reference
Alzheimer’s disease: the cholesterol connection
10.1038/nn0403-345 · doi-reference
Effects of physical exercise on Alzheimer’s disease biomarkers: a systematic review of intervention studies
10.3233/jad-170567 · doi-reference
Associations between multidomain modifiable dementia risk factors with AD biomarkers and cognition in middle-aged and older adults
10.1016/j.neurobiolaging.2024.02.015 · doi-reference
Plasma biomarkers of Alzheimer’s disease and neurodegeneration according to sociodemographic characteristics and chronic health conditions
10.14283/jpad.2024.142 · doi-reference
Sex-associated differences in plasma and cerebrospinal fluid biomarkers in early-onset Alzheimer’s disease
10.1002/alz.079392 · doi-reference
Plasma biomarkers for Alzheimer’s disease in relation to neuropathology and cognitive change
10.1007/s00401-022-02408-5 · doi-reference
Diagnostic and predictive power of plasma proteins in Alzheimer's disease: a cross-sectional and longitudinal study in China
10.1038/s41598-024-66195-7 · doi-reference
The relationship between blood lipids and plasma amyloid beta is depend on blood pressure: a population-based cross-sectional study
10.1186/s12944-020-1191-4 · doi-reference
Association of Kidney Function with Development of Alzheimer disease and other dementias and dementia-related blood biomarkers
10.1001/jamanetworkopen.2022.52387 · doi-reference
Impact of pre-analytical sample handling factors on plasma biomarkers of Alzheimer's disease
10.1111/jnc.15757 · doi-reference
Actigraphy-estimated sleep and 24-hour activity rhythms and the risk of dementia
10.1002/alz.12122 · doi-reference
The role of actigraphy in the study of sleep and circadian rhythms
10.1093/sleep/26.3.342 · doi-reference
Smaller pineal gland is associated with rapid eye movement sleep behavior disorder in Alzheimer's disease
10.1186/s13195-020-00725-z · doi-reference
The REM sleep behavior disorder screening questionnaire—a new diagnostic instrument
10.1002/mds.21740 · doi-reference
Subjectively reported sleep quality and excessive daytime somnolence in Parkinson’s disease with and without dementia, dementia with Lewy bodies and Alzheimer’s disease
10.1002/gps.1709 · doi-reference
A new method for measuring daytime sleepiness: the Epworth sleepiness scale
10.1093/sleep/14.6.540 · doi-reference
Mapping the extent of the literature and psychometric properties for the physical activity scale for the elderly (PASE) in community-dwelling older adults: a scoping review
10.1186/s12877-024-05332-3 · doi-reference